Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q969G3

UPID:
SMCE1_HUMAN

ALTERNATIVE NAMES:
BRG1-associated factor 57

ALTERNATIVE UPACC:
Q969G3; B3KMC1; B4DFR4; C0IMW4; C0IMW5; C0IMW7; H7C3F6; O43539

BACKGROUND:
The protein SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1, with alternative name BRG1-associated factor 57, is essential for chromatin remodeling. It facilitates transcriptional activation and repression, and is integral to the switch from proliferating neural stem cells to postmitotic neurons, indicating its critical role in neural development.

THERAPEUTIC SIGNIFICANCE:
Given its association with conditions such as Meningioma and Coffin-Siris syndrome 5, the protein presents a promising avenue for the development of novel therapeutic approaches. The exploration of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1's function could lead to breakthroughs in treatment strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.